Replies to post #145614 on NanoViricides Inc. (NNVC)

[KMBJN]

Yes, that's the claim, that NV-CoV-2 is effective against different CoVs that use different cellular receptors for entry, both ACE2 and CD13/APN (they didn't comment on DPP4 CoVs like MERS). The question is how can it block both when the ligand was only designed to mimic ACE2 and thus those CoVs that use ACE2?

Thanks for sharing the video of the presentation. It has a whole 35 views so far.